Navigation Links
MUSC Research Offers Hope for Those Resistant to Depression,Treatment

CHARLESTON, S.C., March 23, 2007 /PRNewswire/ -- Researchers at the Medical University of South Carolina (MUSC) have announced the results of a two-year study, which tested the long-term antidepressant response to VNS (Vagus Nerve Stimulation) Therapy(TM) in patients with treatment-resistant depression (TRD). The study, of which Mark S. George, M.D., MUSC Distinguished Professor of Psychiatry, Radiology and Neurosciences is a lead author, will appear in the April 2007 issue of the International Journal of Neuropsychopharmacology. Results showed that, of the patients who responded to VNS Therapy, either early or later in treatment, the majority continued to experience significant clinical benefit for up to 24 months. VNS Therapy is the first and only treatment for TRD to demonstrate such long-term improvements.

Patients included in this study, led by Harold A. Sackeim, PhD, of , experienced severe chronic depression which proved to be treatment-resistant. The study participants had a 50 percent improvement in their depressive symptoms at either three months or a year after being treated with VNS Therapy. Between 61 and 79 percent of patients sustained this response for 24 months. The durability of response was not attributable to alterations in other treatments.

"These data showing durability of response with VNS Therapy are pretty remarkable under any circumstances, but particularly for the patient population studied here," said George. "Patients with TRD don't respond to medications, and even when they do, they often develop tolerance after 6 months, and the depression returns. These findings regarding long-term sustained effectiveness are very encouraging for psychiatrists and patients with treatment-resistant depression. This study analysis provides additional confirmation that, at least for some patients, the benefits of VNS Therapy for TRD are long-term and improve over time."

Many peo ple with major depression relapse frequently, often despite numerous other treatment trials. More than 40 percent of patients experience a recurrence after two years and more than 60 percent experience recurrence after five years. Eighty to 90 percent of those patients having experienced two or more episodes of depression will have additional episodes. Electroconvulsive therapy (ECT) is considered by many psychiatrists as the most effective acute intervention for TRD. However, the majority of TRD patients relapse during the first year following response to ECT. This study shows that VNS Therapy is an effective long-term treatment option for some of these patients.

The FDA approved VNS Therapy as an adjunctive long-term treatment of chronic or recurrent depression for patients 18 years of age or older who are experiencing a major depressive episode and have not had an adequate response to four or more adequate antidepressant treatments. VNS Therapy is also FDA- approved as an adjunctive therapy used to reduce the frequency of seizures in adults and adolescents over 12 years of age with partial onset seizures that are refractory to antiepileptic medications. In addition to treatment- resistant depression and pharmacoresistant epilepsy indications, VNS Therapy is at various stages of research as potential treatments for anxiety disorders, Alzheimer's disease, bulimia, chronic headache/migraine and morbid obesity.

CONTACT: Tim Gehret of Medical University of South Carolina,+1-843-792-2626

Web site: http://www.musc.edu/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. NIEHS Researchers Identify Enzyme Critical in DNA Replication
2. Stanford Researchers Find Brain Pathway of Depression in Rats
3. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
4. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
5. Researchers Discover Method for Identifying How Cancer Evades the Immune System
6. Infertile Voice Supports Stem Cell Research: RESOLVE Calls for Patient Options in Using Frozen Embryos
7. Fact Sheet: Advancing Stem Cell Research While Respecting Moral Boundaries
8. President Bush Ignores Americas Plea for Support of Stem Cell Research
9. Researchers Discover Gene For Rare Skin Disorder
10. The Christopher and Dana Reeve Foundation Expresses Disappointment Over President Bushs Veto of the Stem Cell Research Enhancement Act
11. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
Breaking Medicine Technology:
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... ... Haute Living, is proud to recognize Dr. Barry M. Weintraub as a prominent ... “the most beautiful women in the world, and the most handsome men, look ...
Breaking Medicine News(10 mins):